The most striking improvement in AML therapy was achieved by the treatment of acute promyelocytic leukemia (APL) using the retinoic acid (RA) receptor- (RAR-) specific ligand, all-trans RA (ATRA) [2, 3]. This evidence concerns the gene RARA and acute myeloid leukemia.